CD83 and hepatocellular carcinoma: Moreover, in hepatoma-transplanted murine models, sFGL2 blockage promoted MHCII and CD83 expression and downregulated the expression of CD31, which is reportedly an immune-inhibitory marker on the DC surface [32].